Clinical Trial Update: Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC

View source ↗

Summary

This clinical trial update outlines planned research on resistance mechanisms and sequential treatment strategies following first-line lorlatinib in ALK-positiv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: ALK-Positive NSCLC | Status: NOT_YET_RECRUITING